# A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

> **NCT05446688** · PHASE2 · UNKNOWN · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** 6MW3211

## Key facts

- **NCT ID:** NCT05446688
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446688, "A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05446688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*